Glycaemic control + weight
CagriSema in type 2 diabetes
REIMAGINE 2 enrolled 2,713 participants and found greater HbA1c reduction with CagriSema 2.4/2.4 mg versus semaglutide 2.4 mg; gastrointestinal disorders were the most common adverse events.
Exact-combination evidence
Phase III combination evidence
REIMAGINE 2 enrolled 2,713 participants and found greater HbA1c reduction with CagriSema 2.4/2.4 mg versus semaglutide 2.4 mg; gastrointestinal disorders were the most common adverse events. The combination result does not establish that cagrilintide monotherapy has the same efficacy.
Human combination evidence
Yes — REIMAGINE 1/2 and REDEFINE 2
Combination safety
Yes
How to read this combination page
Component evidence and direct combination evidence are kept separate. Study doses or regimens, where mentioned, describe the cited research only and are not recommendations for personal use.